All In Biotech

Drug Trial Radar · NCT07706777

Clinical Study of HRS-2129 for Acute Gouty Arthritis

Clinical Study on Safety and Efficacy of HRS-2129 for Acute Gouty Arthritis

Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Aug 19, 2026

Primary completion

Oct 2026

Study completion Nov 2026

Sponsor

Sponsor type
Industry
First posted
Jul 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is being conducted to evaluate the safety, and efficacy of HRS-2129 for acute gouty arthritis. To explore the reasonable dosage of HRS-2129 for acute gouty arthritis.

Conditions

  • Acute Gouty Arthritis

Interventions

  • HRS-2129 TabletDrug

    HRS-2129 Tablet; high dose

  • HRS-2129 TabletDrug

    HRS-2129 Tablet; low dose

  • PlaceboDrug

    HRS-2129 Tablet Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline inVisual Analogous Scale pain score at 24 hours post first doseTime frame: from ICF signing date to 24 hours after first dose

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • The Third Affiliated Hospital of Sun Yat-sen University

    Guangzhou, Guangdong, China · Recruiting

  • Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School

    Nanjing, Jiangsu, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.